Analiza porównawcza przebiegu neutropenii po chemioterapii i zastosowaniu czynnika wzrostu kolonii granulocytarnych lub jego formy pegylowanej

Abstract

IntroductionGranulocyte colony stimulating factor (G-CSF, filgrastim) is used in oncology to accelerate granulocyte recovery. Pegfilgrastim is its pegylated derivative with prolonged activity. ObjectiveComparative analysis of effectiveness of pegfilgrastim or filgrastim applied after chemotherapy in children with cancer. Material and methodsA total number of 18 patients receiving filgrastim and 12 patients receiving pegfilgrastim were enrolled into analysis. ResultsThere were no significant differences in clinical course between the two groups of patients. However, duration of severe neutropenia was significantly shorter for patients receiving pegfilgrastim than those receiving filgrastim (4.5 vs 7.5 days, p=0.017), and the difference in the duration of very severe neutropenia and duration of severe leukopenia almost reached statistical significance. Among patients receiving pegfilgrastim, incidence of febrile neutropenia was significantly Iower (10/22 vs 23/26, ie 45% vs 88%, p=0.003), but the median duration of fever was higher in this group (3 vs 2 days, p=0.008). Patients did not report adverse symptoms associated with the use of pegfilgrastim or filgrastim. ConclusionsPegylated form of filgrastim with prolonged activity, is a safe drug and well tolerated by children with cancer after chemotherapy. In comparison with filgrastim, the application of pegfilgrastim gives the possibility to reduce the severe neutropenia and reduce the incidence of febrile neutropenia.